Unfortunately, the only clinical trial incorporating a patient with advanced NSCLC could not describe objective anti-tumor effects after anti-EPHA2 DS-8895a antibody administration, hence questioning the results of the preclinical studies. This evidence concerns the gene EPHA2 and non-small cell lung carcinoma.